p300 Acetyltransferase Activity Differentially Regulates the ...

4 downloads 0 Views 1001KB Size Report
Mar 9, 2011 - Co-transfection of FOXO1, FOXO3a or FOXO4 with the p300 constructs. 37 further identified p300 HAT activity to also differentially regulate the ...
Articles in PresS. Am J Physiol Cell Physiol (March 9, 2011). doi:10.1152/ajpcell.00255.2010

1 1

p300 Acetyltransferase Activity Differentially Regulates the

2

Localization and Activity of the FOXO Homologues in Skeletal

3

Muscle

4

Sarah M. Senf1, Pooja B. Sandesara2, Sarah A. Reed2, Andrew R. Judge1,2

5

1Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, Florida,

6

USA; 2 Department of Physical Therapy, University of Florida, Gainesville, Florida, USA

7 8

Corresponding author:

9

Andrew R. Judge,

10

Department of Physical Therapy

11

J303, Biomedical Sciences Building

12

1275 Center Drive

13

University of Florida,

14

Gainesville, FL 32610

15

USA

16

Tel: 352-273-9220

17

Fax: 352-273-6109

18

E-mail: [email protected]

19 20 21 22 23 24 25

Running title: p300 HAT activity represses FOXO in muscle

Copyright © 2011 by the American Physiological Society.

2 26

ABSTRACT

27

The Forkhead Box O (FOXO) transcription factors regulate diverse cellular processes, and in

28

skeletal muscle are both necessary and sufficient for muscle atrophy. Although the regulation of

29

FOXO by Akt is well evidenced in skeletal muscle, the current study demonstrates that FOXO is

30

also regulated in muscle via the acetyltransferase (HAT) activities of p300/CBP. Transfection of

31

rat soleus muscle with a dominant-negative (d.n.) p300, which lacks HAT activity and inhibits

32

endogenous p300 HAT activity, increased FOXO reporter activity and induced transcription

33

from the promoter of a bona fide FOXO target gene, atrogin-1. Conversely, increased HAT

34

activity via transfection of either WT p300 or WT CBP repressed FOXO activation in vivo in

35

response to muscle disuse, and in C2C12 cells in response to dexamethasone & acute starvation.

36

Importantly, manipulation of HAT activity differentially regulated the expression of various

37

FOXO target-genes. Co-transfection of FOXO1, FOXO3a or FOXO4 with the p300 constructs

38

further identified p300 HAT activity to also differentially regulate the activity of the FOXO

39

homologues. Markedly, decreased HAT activity strongly increased FOXO3a transcriptional

40

activity, while increased HAT activity repressed FOXO3a activity and prevented its nuclear

41

localization in response to nutrient deprivation. In contrast, p300 increased FOXO1 nuclear

42

localization. In summary, this study provides the first evidence to support the acetyltransferase

43

activities of p300/CBP in regulating FOXO signaling in skeletal muscle, and suggests that

44

acetylation may be an important mechanism to differentially regulate the FOXO homologues and

45

dictate which FOXO target-genes are activated in response to varying atrophic stimuli.

46 47 48

Key Words: HAT, muscle atrophy, disuse, cachexia, gene regulation, atrogin-1

3 49

INTRODUCTION

50

FOXO signaling has been implicated in skeletal muscle atrophy associated with sepsis

51

(9), starvation (24, 27), diabetes (28), cancer (27), aging (16, 27) and heart failure (44). More

52

direct work, using genetic approaches, demonstrate that at least two of the FOXO homologues,

53

FOXO1 (23) and FOXO3a (43), are sufficient to cause skeletal muscle atrophy, in vivo. Perhaps

54

more importantly, blocking FOXO transactivation prevents at least 40% of disuse muscle fiber

55

atrophy (39, 45), further demonstrating the requirement of FOXO for the normal atrophy

56

phenotype in a physiological model of muscle atrophy. Given the significance of FOXO in the

57

regulation of muscle mass, identifying the immediate upstream regulators of FOXO may lead to

58

the development of specific countermeasures to prevent muscle wasting.

59

The regulation of FOXO signaling by Akt has been extensively characterized in a variety

60

of cell types, including skeletal muscle (2, 26, 43). In response to growth conditions or growth

61

factor stimuli the IGF-1/PI3K/Akt pathway is activated, which leads to FOXO phosphorylation

62

by Akt on specific residues, which promotes the cytosolic retention and inactivation of FOXO (2,

63

42). In skeletal muscle, direct evidence to support the IGF-1/PI3K/Akt pathway in regulating

64

FOXO can be found in several studies (26, 43, 48). Decreases in this signaling pathway in

65

skeletal muscle during physiological conditions of muscle atrophy such as starvation and muscle

66

disuse are thought to contribute to FOXO activation. However, increasing evidence demonstrate

67

FOXO-signaling to be controlled via additional post-translational modifications and protein-

68

protein interactions which are distinct from Akt-mediated phosphorylation (19, 51). Yet, many of

69

these additional regulatory mechanisms have yet to be thoroughly explored in skeletal muscle. If

70

similar control mechanisms indeed exist in skeletal muscle to modulate FOXO activity, this

4 71

could potentially open up new avenues for therapeutically blocking FOXO function and the

72

associated muscle atrophy during physiological conditions of muscle wasting.

73

One such mechanism of FOXO regulation identified in multiple cell types, involves the

74

regulation of FOXO-dependent transcription by the histone acetyltransferase (HAT) proteins,

75

p300 and CREB binding protein (CBP) (11, 14, 35). These HAT proteins each possess an

76

intrinsic acetyltransferase activity which catalyzes the transfer of an acetyl group to specific

77

lysine residues on target proteins (10, 11, 32). Although HATs are most well known for

78

regulating gene transcription through histone acetylation and relaxation of chromatin structure at

79

gene promoters (12, 31), HATs also play an important role in regulating the activity of a variety

80

of transcription factors, including p53, MyoD, HIF-1alpha, as well as the FOXO transcription

81

factors (47, 52). HATs may regulate transcription factor activity through various mechanisms

82

which include interaction and recruitment of factors to target gene promoters, via acting as

83

adaptor molecules facilitating protein-protein interactions, and through direct acetylation of

84

transcription factors or other necessary co-factors which thereby alter transcription factor activity

85

(25). Evidence for HAT-mediated regulation of the FOXO transcription factors can be found in

86

multiple cell types. Interestingly however, the resulting effect of HATs on FOXO appears to be

87

cell-type specific and/or specific to the FOXO homologue.

88

FOXO1-dependent transcription from the IGFBP-1 promoter reporter in H4IIE rat hepatoma

89

cells, which requires p300 HAT activity (35). Similarly, p300 increases FOXO3a-dependent

90

transcription from the Bim promoter in human embryonic kindey cells (HEK293T) (34). In

91

contrast, p300 represses FOXO4-induced transcription of GADD45, p27, p21 and MnSOD in

92

HEK293 cells (11). Therefore depending on the cell type, FOXO homologue, and target gene

93

measured, HATs may either repress or activate FOXO-induced transcription, which may reflect

For example, p300 increases

5 94

an important fine-tuning mechanism of FOXO-target gene regulation. However, despite the

95

importance of understanding the mechanisms which lead to FOXO-dependent transcription in

96

skeletal muscle due to its known role in causing muscle atrophy, no data currently exist to

97

suggest whether the acetyltransferase activities of p300/CBP regulate FOXO in skeletal muscle.

98

Therefore, the purpose of the current study was to determine whether HAT proteins regulate the

99

FOXO transcription factors in skeletal muscle, and whether this is altered during conditions of

100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116

muscle wasting.

6 117

MATERIALS AND METHODS

118

Animals

119

Sprague-Dawley male rats (200-225g) were ordered from Charles River Laboratories

120

(Wilmington, MA, USA).

121

Committee approved all animal procedures. UF is accredited by the Association for Assessment

122

and Accreditation of Laboratory Animal Care (#A3377-01). Animals were maintained in a

123

temperature and humidity-controlled facility with a 12-hour light/dark cycle. Water and standard

124

diet were provided ad libitum.

125

Plasmids and Reporter Gene Assays

126

Expression plasmids for WT p300 and the dominant negative (d.n.) p300 mutant (which lacks

127

acetyltransferase activity due to an inactivating point mutation, converting aspartic acid 1399 to

128

tyrosine ) were obtained from Dr. Tso-Pang Yao (Duke University, Durham, NC, USA) and have

129

been previously described (21). The FOXO1 expression plasmid was a gift from Dr. Akiyoshi

130

Fukamizu (University of Tsukuba, Ibaraki, Japan) and has previously been used and described

131

(32). The tagged FOXO1-EGFP plasmid was obtained from Addgene (plasmid 9022), and was

132

deposited by Dr. Domenico Accili (Columbia University, New York, NY, USA) and has

133

previously been described (13). The FOXO4 expression plasmid was a gift from Dr. Boudewijn

134

Burgering (University Medical Center, Utrecht, The Netherlands) and has been previously used

135

and described (53). The FOXO3a expression plasmid was obtained from Addgene (plasmid

136

10710), was deposited by Dr. William Sellers (Novartis, Cambridge, MA) and has been

137

previously used and described (37). The WT FOXO3a-DsRed fusion construct was created via

138

PCR amplification of the FOXO3a cDNA out of the parent vector using primers to create

139

HindIII and SalI restriction sites on the 5’ and 3’ ends of the FOXO3a coding region,

The University of Florida Institutional Animal Care and Use

7 140

respectively. FOXO3a cDNA was then sub-cloned, in frame, into the DsRed2-c1 plasmid.

141

Verification that FOXO3a cDNA was in frame was confirmed via DNA sequencing (DNA

142

Sequencing Core, University of Florida). The d.n.Akt and c.a.Akt expression plasmids were

143

obtained from Addgene (plasmids 12643 & 16244, respectively) and were deposited by Dr.

144

Mien-Chie Hung (The University of Texas, M. D. Anderson Cancer Center, Houston, TX) and

145

have previously been described (58). The DAF-16/FOXO responsive reporter plasmid, the

146

atrogin-1-GL2 promoter reporter plasmid and the d.n.FOXO construct have also been previously

147

used and described (46). pRL-TK-Renilla was purchased from Promega. Plasmid DNA was

148

amplified and isolated from bacterial cultures using Endotoxin-Free Maxi or Mega Prep Kits

149

(Qiagen, Valencia, CA, USA), precipitated in ethanol and re-suspended in 1X sterile filtered

150

phosphate buffered saline (PBS) for in vivo transfections, or Tris-EDTA (TE) buffer for

151

transfections in culture.

152

In vivo, Plasmid Injection and Electroporation.

153

Transfection of plasmid DNA into skeletal muscle, in vivo, has been detailed previously (22, 46).

154

For rat experiments, 10μg each of the expression or control plasmid(s) and 40μg of the reporter

155

plasmid were diluted in a total of 50μl 1XPBS for each solei injection. Standard procedures

156

were used to determine luciferase activity on skeletal muscle homogenates using a Modulus

157

single tube multimode reader (Promega) and have been described previously (46).

158

Animal Models and Muscle Preparation

159

Disuse muscle atrophy via cast immobilization of both hind limbs was induced in rats four days

160

following plasmid injection and has been detailed previously (46).

161

immobilization or weight bearing activity soleus muscles were removed and processed either

162

immediately for RNA isolation or frozen in liquid nitrogen and stored at -80°C until further

After three days of

8 163

biochemical analyses. For experiments using exclusively genetic manipulations, muscles were

164

harvested 7 days post-plasmid injection.

165

Cell Culture Experiments

166

C2C12 cells were cultured on 0.1% gelatin coated 6-well plates in high-glucose DMEM

167

(Invitrogen), 10% fetal bovine serum and 5% CO2. Muscle cells were transfected with plasmid

168

DNA at ~80% confluence using FuGENE® HD Transfection Reagent (Promega Corp, Madison,

169

WI, USA) at a 3.5:1 ratio of reagent to total DNA. Sixteen hours following transfection muscle

170

cells were differentiated into myotubes by incubation in differentiation medium (2% Horse

171

Serum in DMEM). For dexamethasone studies, 6-day differentiated myotubes were treated with

172

either vehicle (water) or 1uM water-soluble dexamethasone (Sigma, St. Louis, MO, USA) in

173

differentiation media for 6 hours and harvested in Passive Lysis Buffer (Promega). In the

174

nutrient deprivation groups, differentiation media was removed from 4-day differentiated cells

175

and Hanks Balanced Salt Solution (HBSS) added for either 2 hours (localization experiments) or

176

6 hours (reporter assays and gene expression) prior to harvest. To inhibit PI3Kinase, 10μM

177

LY294002 (Calbiochem, Merck KGaA, Darmstadt, Germany) or vehicle (ethanol) was added to

178

4-day differentiated myotubes for 6 hours. For reporter experiments, cells were harvested in

179

Passive Lysis Buffer (Promega) and luciferase activity determined by normalizing firefly

180

luciferase activity to pRL-TK Renilla luciferase activity using a Dual-Luciferase® Reporter

181

Assay (Promega).

182

RNA isolation, cDNA synthesis, and RT-PCR

183

RNA isolation and cDNA synthesis from whole muscle was performed using a Trizol-based

184

method as previously described (46). RNA isolation from C2C12 myotubes was performed

185

similarly, following addition of 250uL Trizol per well and vigorous scraping, as previously

9 186

described (33) . cDNA was generated from 1ug of RNA and was used as a template for qRT-

187

PCR using primers for atrogin-1, GenBank NM_133521; MuRF1, GenBank NM_080903;

188

Cathepsin-L, GenBank NM_013156; 4E-BP1, GenBank NM_053857; LC3b, GenBank

189

NM_022867; p21, Genbank NM_080782; Gadd45α, GenBank NM_024127; Foxo1, GenBank

190

NM_001191846; Foxo3a, GenBank NM_001106395; Foxo4, GenBank NM_001106943; or 18S,

191

GenBank X03205.1, which were ordered from Applied Biosystems (Austin, TX, USA). TaqMan

192

probe-based chemistry was used to allow detection of PCR products using a 7300 real-time PCR

193

system (Applied Biosystems), and quantification of gene expression was performed using the

194

relative standard curve method.

195

Western Blotting and Co-Immunoprecipitation Assays

196

Preparation of muscle homogenates and western blotting were performed according to standard

197

procedures and have been described previously (46). Primary antibodies for p300 (#554215, BD

198

Pharmingen, San Jose, CA, USA), FOXO1 (#9454S, Cell Signaling Technology, Boston, MA,

199

USA); phospho-FOXO1 (Ser256) (#9461, Cell Signaling Technology); FOXO3a (SC-11351,

200

Santa Cruz Biotechnology, Santa Cruz, CA, USA); phospho-FOXO3a (Thr32) (SC-12357, Santa

201

Cruz Biotechnology) and FOXO4 (07-1720, Millipore, Billerica, MA), were used according to

202

manufacturer’s directions.

203

Louis, MO, USA) was used to control for equal protein loading and protein transfer. For co-

204

immunoprecipitation assays proteins, 500ug of muscle protein were incubated overnight with

205

either 4ug of Anti-Acetyl Lysine antibody (#05-515) or 4ug of anti-p300 (#05-257) using a

206

Catch and Release Reversible Immunoprecipitation System (#17-500), all from Millipore. The

207

following day, precipitated proteins were washed and subsequently eluted in denaturing buffer,

208

boiled, and western blotting performed for endogenous FOXO3a and FOXO1.

Tubulin primary antibody, (T6074 from Sigma-Aldrich Inc, St.

10 209

Fluorescent Microscropy

210

C2C12 myoblasts were seeded on 6-well plates containing 0.1% gelatin-coated glass coverslips,

211

transfected and differentiated for 4 days. Following treatment, cells were rinsed with PBS and

212

fixed for 30 minutes in 4% paraformaldehyde. Following three washes in PBS, two drops of

213

Vectashield Mounting Medium for Fluorescence, with Dapi, (#H-1200, Vector Laboratories, Inc,

214

Burlingame, CA, USA) was added to each coverslip. A Leica DM5000B microscope (Leica

215

Microsystems Inc., Bannockburn, IL USA) containing GFP (green) and Rhodamine (red) filter

216

cubes was used to visualize FOXO1-EGFP or FOXO3a-DsRed positive myotubes, respectively.

217

A Dapi (blue) filter was used to visualize Dapi-stained nuclei. Images were captured and merged

218

using Leica Application Suite, version 3.5.0.

219

Statistics

220

Data were analyzed using a two-way ANOVA followed by Bonferroni post-hoc comparisons

221

when appropriate (GraphPad Software, San Diego, CA). All data are expressed as the mean ±

222

SEM, and significance was set at P